Drug intelligence / Profile preview

NovDB2

Development stage: Unknown
Lead developer: NovMetaPharma
Modality: Small Molecules
Administration: Oral

Overview

NovDB2 is a first-in-class small molecule drug developed to improve insulin sensitivity, primarily targeting type 2 diabetes mellitus. It is being developed by NovMetaPharma and represents a novel approach in the management of diabetes by enhancing the body's response to insulin. The compound has advanced to Phase 2 clinical trials for type 2 diabetes, including studies in obese populations. While its precise mechanism of action has not been fully elucidated, it is positioned as an innovative agent distinct from existing antidiabetic therapies[1][2][8].

Beyond the preview

Go deeper on NovDB2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovDB2.

Explore the full profile